2548 research outputs found
Sort by
From Rights to Risks: Mental Health Implications for Pregnant Patients Following the Reversal of Roe v. Wade
Get PDF
Uncovering BRASH Syndrome: A Critical Diagnosis in Acute Cardiac and Renal Dysfunction: A Case Report
Get PDFThyrotoxic Periodic Paralysis: Acute Paralysis as the Initial Presentation of Graves\u27 Disease Triggering a Stroke Alert
Get PDF
Elbow Internal Joint Stabilizers: A Single Institution Retrospective Review of Patient Outcomes for Traumatic Elbow Instability
Get PDFExploring the Boundaries of AI: ChatGPT’s Accuracy in Anatomical Image Generation & Bone Identification of the Foot
Get PDFManaging Hemodynamic Support in Mixed Serotonin Syndrome and Severe Bupropion Toxicity: A Case Report
Get PDFNovel Drug Approvals 2024
Get PDFIn 2024, the Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CEDR) approved 50 new drugs. As healthcare professionals, staying up to date on new therapies is vital. There are a wide range of medications that fall into several categories; therefore every professional can find a medication that pertains to their field. Three medications in particular will be described in detail outlining their background, the clinical trials highlighting their efficacy and safety, and lastly the prescribing information. The three medications are as follows, Xanomeline/Trospium Chloride (Cobenfy),Sotatercept-csrk (Winrevair) and Suzetrigine (Journavx).
Xanomeline/trospium chloride (Cobenfy) is a first of its kind as a treatment for adult patients with schizophrenia disorder. This medication is thought to work through the muscarinic receptors, making this medication unique compared to current therapies such as first- and second-generation antipsychotics which exert its mechanism through dopamine receptors. Sotaercept-csrk (Winrevair) is the first and only FDA approved activin signaling inhibitor for the treatment of pulmonary arterial hypertension. This medication can help patients reduce the risk of clinically deteriorating events, improve WHO functional class, and improve exercise capacity by promoting vascular proliferation. Suzetrigine (Journavx) is a first-in-class non-opioid analgesic that is used to treat moderate to severe acute pain in adults. This medication presents a promising alternative for patients who cannot tolerate opioids or are at high risk for opioid-related adverse effects